Stiris Research Inc. awarded extension of Phase II Hormone Refactory Castrate-Resistant Prostate Cancer (HRCPC) study

July 17, 2017 | Stiris

London, ON – July 17, 2017 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces it will be partnering with a specialty pharmaceutical company to ensure safety of subjects with HRCPC previously treated with its oral anti-androgen in a Phase II trial. “We are […]


Stiris Research Inc. hits corporate target of First Patient Visit in a Phase III Global Parkinson’s Study

April 10, 2017 | Stiris

London, ON – April 10th, 2017 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announce they have successfully achieved a corporate milestone target for a US client of First Patient First Visit (“FPFV”) in a global Phase III trial in Parkinson’s disease. “We are […]


Stiris Research Inc. awarded a Phase IIa Venous Leg Ulcer Study

April 3, 2017 | Stiris

London, ON – April 3, 2017 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces that a Canadian biotechnology company has awarded them the US component of their global Phase IIa Venous Leg Ulcer trial. Stiris will launch the US component with the company […]


Stiris Research Inc. collaborates with US biotech to conduct preliminary feasibility in Non-Hodgkin’s Lymphoma

April 2, 2017 | Stiris

London, ON – April 4, 2017 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces it is collaborating with a US biotech company to perform preliminary feasibility in North America for their Phase I/II Non-Hodgkin’s Lymphoma trial. “We are excited to be able to […]


Stiris Research Inc. hits corporate target of First Site Initiation Visit in a Phase III Global Parkinson’s Study

February 28, 2017 | Stiris

London, ON – February 28th, 2017 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announce that they have successfully achieved a corporate milestone target for a US client of First Site Initiation Visit (“SIV”) in a global Phase III trial in Parkinson’s disease. “Stiris […]


Stiris Research Inc. exceeds recruitment targets in Phase II Meniere’s disease study

October 31, 2016 | Stiris

London, ON – October 31, 2016 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces that it has exceeded the expected recruitment targets on a US biotechnology company’s Phase II Meniere’s disease study. “We are excited to see the improvements this treatment will provide, […]


Stiris Research Inc. collaborates with US biotech to conduct their Phase III Global Parkinson’s Study

October 17, 2016 | Stiris

London, ON – October 17, 2016 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announce it has entered into a Master Services Agreement (the “MSA”) with a US biotech company to spearhead their global Phase III trial in Parkinson’s disease (PD). “We are excited […]


Stiris Ranks 124th on the 2016 PROFIT 500

September 15, 2016 | Stiris

– PROFIT magazine unveils 28th annual list of Canada’s Fastest-Growing Companies – London, Ontario (September 15, 2016) Canadian Business and PROFIT today ranked Stiris Research Inc. No. 124 on the 28th annual PROFIT 500, the definitive ranking of Canada’s Fastest-Growing Companies. Published in the October issue of Canadian Business and at PROFITguide.com, the PROFIT 500 […]


Stiris Research’s CEO Ranks No. 9 on the W100

May 16, 2016 | Stiris

London, Ontario (May 16, 2016) PROFIT and Canadian Business today ranked Shantal Feltham, President and CEO of Stiris Research Inc., No. 9 on the 18th annual W100 list of Canada’s Top Female Entrepreneurs. Published today at PROFITguide.com, the W100 ranks female entrepreneurs using a proprietary formula that considers the size, growth rate and profitability of […]


Stiris Research’s CEO Selected for Elite Ivey Program

May 8, 2016 | Stris

London, Ontario – 08 May 2016 – Stiris Research Inc. is pleased to announce that Shantal Feltham, President & CEO has been selected to participate in the 2016 QuantumShift program. QuantumShift is an exclusive invitation-only leadership development program for 40 of Canada’s most promising entrepreneurs. Founded by KPMG Enterprise and the Richard Ivey School of […]